Preclinical evaluation reveals gut microbiota modulation by Lactococcus cremoris FBMS_5810, suggesting health benefits.
This study presents a comprehensive genomic and preclinical evaluation of Lactococcus cremoris FBMS_5810, establishing its taxonomic identity, genomic uniqueness, and safety profile. Genomic analyses identified strain-specific genes linked to adhesion, colonization, and pathogen exclusion, aligning with previously observed in vitro probiotic properties. In vivo studies in healthy mice demonstrated that Lactococcus cremoris FBMS_5810 modulates gut microbiota composition. Specifically, the relative abundance of Muribaculaceae, Erysipelotrichaceae, and Streptococcaceae was significantly increased in the probiotic-treated group, whereas the relative abundance of Ruminococcaceae, Bacteroidaceae, Porphyromonadaceae, and Dehalobacteriaceae was decreased. Administration of Lactococcus cremoris FBMS_5810 was also associated with changes in intestinal gene expression: in the ileum, Tnf and Il1b expression increased, while in the cecum, Zo1 expression was elevated. These findings may indicate a role in supporting intestinal homeostasis and could be linked to reduced susceptibility to diet- and inflammation-related disorders. Overall, these results suggest that Lactococcus cremoris FBMS_5810 may be a useful candidate for further investigation in the development of health-oriented microbial products. By integrating genomic characterization with preclinical evaluation, this study not only highlights Lactococcus cremoris FBMS_5810 as a promising candidate but also provides a systematic approach for the identification and validation of probiotics, advancing both fundamental understanding and translational applications in molecular microbiology.
No takes yet. Share an insight, caveat, or question.
Farmakioti et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: